Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30154454 | 1.00 | MAPT (0.48) | MAPTP2RX7MTNR1BAKR1B1DGAT1 | |
| SCHEMBL138095 | 0.87 | BRD4 (0.44) | MAPTDGAT1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL7976028 | 0.85 | ALDH1A1 (0.45) | MAPTALDH1A1L3MBTL1HPGDGAA | |
| SCHEMBL29738044 | 0.85 | ALDH1A1 (0.45) | MAPTALDH1A1L3MBTL1HPGDGAA | |
| SCHEMBL12069886 | 0.84 | MAPT (0.44) | MAPTP2RX7AKR1B1DGAT1L3MBTL1 | |
| SCHEMBL2130306 | 0.84 | PDPK1 (0.52) | MAPTP2RX7MTNR1BAKR1B1BMP1 | |
| SCHEMBL31342163 | 0.84 | MAPT (0.44) | MAPTP2RX7AKR1B1DGAT1L3MBTL1 | |
| SCHEMBL10833911 | 0.83 | HPGD (0.42) | MTNR1BALDH1A1L3MBTL1SMN1; SMN2PYCR1 | |
| SCHEMBL3967997 | 0.83 | SMN1; SMN2 (0.48) | P2RX7ALDH1A1SMN1; SMN2GAATDP1 | |
| SCHEMBL30106457 | 0.83 | HPGD (0.42) | MTNR1BALDH1A1L3MBTL1SMN1; SMN2PYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4695240-A2 | CYCLIC VINYL SULFONE WRN INHIBITORS | Nimbus Wadjet, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12516041-B2 | Crystal forms of GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2026-01-06 | — | — | US | disclosed |
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| EP-4228753-B1 | CRYSTAL FORMS OF GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2025-07-30 | — | — | EP | disclosed |
| WO-2008051404-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| CN-101094827-A | Benzene compound having two or more substituents | SANKYO CO (JP) | 2007-12-26 | — | — | CN | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1597246-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-0874826-A1 | NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1998-11-04 | — | — | EP | disclosed |
| CN-1178525-A | Substituted phenyl compounds as endothelin antagonists | RHONE POULEUC RORER LTD (GB) | 1998-04-08 | — | — | CN | disclosed |
| WO-1997024331-A1 | NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | MAPT 3357/4885P2RX7 1719/4885MTNR1B 923/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | MAPT 4555/4885P2RX7 1425/4885MTNR1B 44/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | MAPT 389/4885P2RX7 957/4885MTNR1B 4336/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | MAPT 383/4885P2RX7 976/4885MTNR1B 4325/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | MAPT 3912/4885P2RX7 771/4885MTNR1B 3184/4885 |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | MAPT 3475/4885P2RX7 2745/4885MTNR1B 2785/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | MAPT 3475/4885P2RX7 2745/4885MTNR1B 2785/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | MAPT 389/4885P2RX7 957/4885MTNR1B 4336/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MAPT 3314/4885P2RX7 201/4885MTNR1B 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.